IHC technology is used commonly to diagnose Xp11.2 tRCC and TFE3 protein is the most distinctive immunohistochemical feature of Xp11 tRCC. This evidence concerns the gene TFE3 and renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions.